# Sapu003 in Advanced mTOR-sensitive Solid Tumors

> **NCT07369505** · PHASE1 · RECRUITING · sponsor: **SAPU NANO (US) LLC** · enrollment: 27 (estimated)

## Conditions studied

- Breast Cancer Metastatic
- Renal Cell Carcinoma (RCC)
- Neuroendocrine Tumors
- Tuberous Sclerosis Complex (TSC)
- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Sapu003
- **DRUG:** Exemestane 25 MG

## Key facts

- **NCT ID:** NCT07369505
- **Lead sponsor:** SAPU NANO (US) LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07369505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07369505, "Sapu003 in Advanced mTOR-sensitive Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07369505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*